

March 26, 2014



Arch Therapeutics Co-Founder Rutledge Ellis-Behnke, PhD Presents at Two Scientific Meetings in March

Discusses AC5(TM) at the Brainstorming Neuromodulation Workshop and 4th Annual Meeting of American Society of Nanomedicine

WELLESLEY, MA -- (Marketwired) -- 03/26/14 -- Rutledge Ellis-Behnke, PhD, co-founder and inventing scientist at Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or "the Company"), a life sciences company and developer of the AC5 Surgical Hemostatic Device™, a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, presents his work using AC5™ at two scientific meetings.

At the upcoming 4th Annual Meeting of the American Society for Nanomedicine in Rockville, Maryland on March 28-30, Dr. Ellis-Behnke will present his hemostasis and tissue stabilization work using self-assembling compositions, including AC5 and other compositions that have been licensed to Arch. Dr. Ellis-Behnke will present on Saturday, March 30 at 9:25 AM EST in a talk titled "New Molecular Medical Devices: A Framework, Objective Measures and Treatments That Can Help Restore the Body to a Pre-injury State."

Information about the American Society for Nanomedicine may be found on their website at the following link <http://amsocnanomed.org>.

Dr. Ellis-Behnke noted, "The use of AC5 to control bleeding during surgery also stabilizes the tissue, which increases the stability of any implantable device. By quickly stopping bleeding, there is little or no edema and the leads will stay where they are placed. Revisions can be greatly reduced. Additionally, through the stabilization of tissue and hemostatic activity, the severity of the damage from trauma and disease can be significantly mitigated, thus reducing recovery time and the risk of developing secondary damage or infection."

He continued, "Arch Therapeutics' work is of vital importance in this field as it is instrumental in understanding how to translate these discoveries into commercially viable processes and products designed to fulfill areas of extraordinary medical need."

Also, at the recent "Brainstorming Neuromodulation" workshop in Carmel, California held on March 14-16, Dr. Ellis-Behnke showed how AC5 stops bleeding during brain surgery. This biannual, invitation-only workshop was organized by Bay Area neurologist Russell Andrews, MD, Medical Advisor for Neurosurgery at NASA Ames Research Center and President of the International Conference on Neuroprotective Agents.

Terrence W. Norchi, M.D., Chief Executive Officer of Arch Therapeutics, said, "We continue to be grateful to Dr. Ellis-Behnke for his work on behalf of the Company, both in terms of his scientific contributions to the development of AC5 and his ongoing outreach to the scientific community to convey AC5's unique benefits."

About Arch Therapeutics, Inc.

Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as AC5™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.

Find out more at www.archtherapeutics.com.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

On Behalf of the Board,
Terrence W. Norchi, MD
Arch Therapeutics, Inc.

Contact:

ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com

Source: Arch Therapeutics, Inc.